31s. Yeganeh N, Kreitchmann R, Klausner JD, Leng M, Gorbach P, Nielsen-Saines K**.** Prevalence of sexually transmitted infections in pregnant women and their partners in Porto Alegre, Brazil. IAS Conference on HIV Science. Mexico City, Mexico; 2019.

32s. Dionne-Odom J 2018;Pages. Accessed at https://clinicaltrials.gov/ct2/show/NCT03431168. Accessed 10/21/2019 2019.

33s. ter Kuile FO, Madanitsa MM 2017;Pages. Accessed at https://ClinicalTrials.gov/show/NCT03208179. Accessed 2/10/2020 2020.

34s. Kotloff K 2019;Pages. Accessed at https://ClinicalTrials.gov/show/NCT03909737. Accessed 1/14/2020 2020.

35s. Chico RM, Chandramohan D 2019;Pages. Accessed at https://clinicaltrials.gov/ct2/show/NCT04189744. Accessed 12/31/2019 2019.

36s. Klebanoff MA, Carey JC, Hauth JC, et al.Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic *Trichomonas vaginalis* infection. N Engl J Med. 2001; 345(7):487-93.

37s. Coker AL**.** Does physical intimate partner violence affect sexual health? A systematic review. Trauma Violence Abuse. 2007; 8(2):149-77.

38s. Unger JA, Matemo D, Pintye J, et al.Patient-delivered partner treatment for chlamydia, gonorrhea, and trichomonas infection among pregnant and postpartum women in Kenya. Sex Transm Dis. 2015; 42(11):637-42.

39s. Wynn A, Moucheraud C, Moshashane N, et al.Using partner notification to address curable sexually transmitted infections in a high HIV prevalence context: a qualitative study about partner notification in Botswana. BMC Public Health. 2019; 19(Suppl 1):606.

40s. Yeganeh N, Simon M, Dillavou C, et al.HIV testing of male partners of pregnant women in Porto Alegre, Brazil: a potential strategy for reduction of HIV seroconversion during pregnancy. AIDS Care. 2014; 26(6):790-4.

41s. Medina-Marino A, Mudau M, Peters R, et al.Persistent *Chlamydia trachomatis*, *Neisseria gonorrhoeae* or *Trichomonas vaginalis* positivity after treatment among human immunodeficiency virus-infected pregnant women. Int J STD AIDS. *In press*.

42s. Guy RJ, Causer LM, Klausner JD, et al.Performance and operational characteristics of point-of-care tests for the diagnosis of urogenital gonococcal infections. Sex Transm Infect. 2017; 93(S4):S16-s21.

43s. Cristillo AD, Bristow CC, Peeling R, et al.Point-of-care sexually transmitted infection diagnostics: proceedings of the STAR Sexually Transmitted Infection-Clinical Trial Group Programmatic Meeting. Sex Transm Dis. 2017; 44(4):211-8.

44s. Kelly H, Coltart CEM, Pant Pai N, et al.Systematic reviews of point-of-care tests for the diagnosis of urogenital Chlamydia trachomatis infections. Sex Transm Infect. 2017; 93(S4):S22-s30.

45s. Foundation for Innovative New Diagnostics 2019;Pages. Accessed at https://www.finddx.org/pricing/genexpert/. Accessed 12/31/2019 2019.

46s. Ong JJ, Chen M, Hocking J, et al.Chlamydia screening for pregnant women aged 16-25 years attending an antenatal service: a cost-effectiveness study. Bjog. 2016; 123(7):1194-202.

47s. Ditkowsky J, Shah KH, Hammerschlag MR, Kohlhoff S, Smith-Norowitz TA**.** Cost-benefit analysis of *Chlamydia trachomatis* screening in pregnant women in a high burden setting in the United States. BMC Infect Dis. 2017; 17(1):155.

48s. Wynn A, Moucheraud C, Morroni C, Ramogola-Masire D, Klausner JD, Leibowitz A**.** Scaling up diagnostic-driven management of sexually transmitted infections in pregnancy. Lancet Infect Dis. 2019; 19(8):809-10.

49s. Shannon CL, Bristow C, Hoff N, et al.Acceptability and feasibility of rapid chlamydial, gonococcal, and trichomonal screening and treatment in pregnant women in 6 low- to middle-income countries. Sex Transm Dis. 2018; 45(10):673-6.

50s. Badman SG, Vallely LM, Toliman P, et al.A novel point-of-care testing strategy for sexually transmitted infections among pregnant women in high-burden settings: results of a feasibility study in Papua New Guinea. BMC Infect Dis. 2016; 16:250.

51s. Morikawa E, Mudau M, Olivier D, et al.Acceptability and feasibility of integrating point-of-care diagnostic testing of sexually transmitted infections into a South African antenatal care program for HIV-infected pregnant women. Infect Dis Obstet Gynecol. 2018; 2018:3946862.

52s. Herbst de Cortina S, Bristow CC, Joseph Davey D, Klausner JD**.** A systematic review of point of care testing for *Chlamydia trachomatis*, *Neisseria gonorrhoeae*, and *Trichomonas vaginalis*. Infect Dis Obstet Gynecol. 2016; 2016:4386127.

53s. Harries AD, Lin Y, Kumar AMV, et al.What can National TB Control Programmes in low- and middle-income countries do to end tuberculosis by 2030? F1000Research. 2018; 7.

54s. Lee AC 2020;Pages. Accessed at https://clinicaltrials.gov/ct2/show/NCT04171388. Accessed January 20, 2020 2020.

55s. Wiesenfeld HC, Manhart LE**.** *Mycoplasma genitalium* in Women: Current Knowledge and Research Priorities for This Recently Emerged Pathogen. J Infect Dis. 2017; 216(suppl\_2):S389-s95.